Amgen Inc. reports $36.75 billion revenue for fiscal year ended December 31, 2025, up 10%

ยท AMGN

Amgen Inc. reported revenue of $36.75 billion for the year ended December 31, 2025, an increase of 10% from the previous year ($33.42 billion).

For the same period it posted net income of $7.71 billion, up 88.5%, or $14.23 per diluted share (7.56 a year earlier).

That is a net margin of 21%.

On Sanad's AAOIFI Standard 21 screen, Amgen Inc. is currently compliant: interest-bearing debt is 21.8% of market capitalisation (limit 30%), and impure income is 1.1% of revenue (limit 5%).

Source: 10-K filed with the U.S. Securities and Exchange Commission on February 13, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Amgen Inc. news